

Phase I Trial of Nanoparticle Albumin-Bound Paclitaxel in Combination with Gemcitabine in Patients with Thoracic Malignancies

Thomas E. Stinchcombe, MD,*† Mark A. Socinski, MD,* Carrie B. Lee, MD,*
D. Neil Hayes, MD, MPH,* Dominic T. Moore, MPH,‡ Richard M. Goldberg, MD,†§
and E. Claire Dees, MD†

Background: Nab-paclitaxel has a different toxicity profile than solvent-based paclitaxel including a lower rate of severe neutropenia. This trial was designed to determine the maximum tolerated dose and dose limiting toxicities (DLT) of nab-paclitaxel in combination with gemcitabine.

Methods: Patients were required to have a performance status of 0 to 1, ≤three prior cytotoxic chemotherapy regimens, and preserved renal, hepatic, and bone marrow function. Patients received gemcitabine 1000 mg/m² on days 1, 8 in all cohorts, and nab-paclitaxel at doses of 260, 300, 340 mg/m² every 21 days depending on the treatment cohort (1 cycle = 21 days). DLT were assessed after the first cycle, and doses were escalated in cohorts of 3 to 6 patients.

Results: Eighteen patients were consented and 15 patients are evaluable [median age 62 years (range, 35–75); median number of prior treatments 3 (range, 1–4); tumor types: non-small cell lung cancer (NSCLC) (*n* = 8), small cell lung cancer (SCLC) (*n* = 6), and esophageal cancer (*n* = 1)]. At a nab-paclitaxel dose of 300 mg/m², 1 of 6 pts experienced a DLT (omission of day 8 gemcitabine due to absolute neutrophil count <500), and at an nab-paclitaxel dose of 340 mg/m² 2 of 3 patients experienced a DLT (1 pt grade 3 rash and pruritus; 1 pt grade 3 fatigue and anorexia). Responses were observed in NSCLC and SCLC.

Conclusions: The maximum tolerated dose of nab-paclitaxel is 300 mg/m² in combination with gemcitabine 1000 mg/m² on days 1, 8 every 21 days. This combination demonstrated activity in previously treated NSCLC and SCLC patients.

Key Words: Abraxane, Non-small cell lung cancer, Small cell cancer, Esophageal cancer, ABI-007, Taxane.

(*J Thorac Oncol.* 2008;3: 521–526)

Paclitaxel has demonstrated significant activity, either as a single agent or in combination with other chemotherapeutic or biologic agents in the treatment of breast, ovarian, lung, and squamous cell cancers of the head and neck. However, paclitaxel has several burdensome toxicities including hypersensitivity reactions, sensory neuropathy, myelosuppression, and mild nausea.¹ Nanoparticle albumin-bound paclitaxel (nab-paclitaxel, ABI-007, Abraxane), a solvent-free formulation of paclitaxel, has recently been approved by the United States Food and Drug Administration for use in treatment of metastatic breast cancer, and has some practical advantages over standard formulation paclitaxel including a lack of hypersensitivity reactions and shorter infusion time. A phase III clinical trial compared paclitaxel with nab-paclitaxel in patients with metastatic breast cancer.² Patients who were treated with nab-paclitaxel experienced a significantly higher response rate, and time to tumor progression in comparison to paclitaxel. Patients who were treated with nab-paclitaxel experienced a significantly lower rate of grade 4 neutropenia, but had a higher rate of grade 3 sensory neuropathy in comparison to patients treated with paclitaxel. Phase II trials with single agent nab-paclitaxel and in combination with carboplatin have revealed significant activity in non-small cell lung cancer (NSCLC).^{3–6} A phase III trial comparing carboplatin and paclitaxel versus carboplatin and nab-paclitaxel has been initiated in patients with advanced NSCLC.

Standard first-line chemotherapy for advanced NSCLC is a platinum-based doublet therapy; however, nonplatinum doublets are an acceptable alternative.⁷ Gemcitabine and paclitaxel is a nonplatinum combination that is used to treat advanced non-small cell lung cancer^{8,9} and metastatic breast cancer.¹⁰ However, there are significant differences in the standard doses and toxicities between nab-paclitaxel and paclitaxel, and thus the potential for additive toxicity with the combination of nab-paclitaxel and gemcitabine. Therefore, we performed a phase I trial to determine the maximum tolerated dose (MTD) and the

*Multidisciplinary Thoracic Oncology Program, †Developmental Therapeutics Group, ‡Division of Biostatistics and Data Management, §Gastrointestinal Malignancies Group, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Disclosure: Dr. Stinchcombe has received research funding from Abraxis Bioscience and is on the speaker's bureau at Lilly Oncology; Dr. Socinski has received research funding from Abraxis Bioscience and Lilly Oncology and is on the speaker's bureau at Lilly; Dr. Goldberg is a consultant for Lilly Oncology.

Address for correspondence: Thomas E. Stinchcombe, MD, 3009 Old Clinic Building Cb 7305, Chapel Hill, NC 27599-7305. E-mail: Thomas_Stinchcombe@med.unc.edu

Copyright © 2008 by the International Association for the Study of Lung Cancer

ISSN: 1556-0864/08/0305-0521

dose limiting toxicities (DLT) of nab-paclitaxel in combination with a standard dose and schedule of gemcitabine.^{8,9}

PATIENTS AND METHODS

Patients were required to have a cytologically or histologically confirmed advanced solid tumor, and a preserved functional status, organ function, a life expectancy of 8 weeks, and be able to provide informed consent. Patients who had received >3 lines of cytotoxic chemotherapy for metastatic disease or were considered heavily pretreated (as defined in Table 1) were excluded; however, there was no exclusion criterion related to prior taxane therapy. Patients were required to meet all the inclusion and exclusion criteria (Table 1). Toxicity was assessed after each cycle using the National Cancer Institute Common Terminology Criteria Adverse Events version 3.0. Dose limiting toxicities were determined after the first cycle, and were defined as on Table 1. Patients were evaluated with weekly complete blood cell count; liver function tests [aspartate aminotransferase, alanine transaminase, alkaline phosphatase, and total bilirubin] and serum creatinine were evaluated before each cycle of chemotherapy. Efficacy was determined using the Response Evaluation Criteria in Solid Tumors.¹¹ Patients were assessed for response after every two cycles (6 weeks). All patients were required to sign informed consent before any study procedures being performed. This trial was reviewed by the protocol review committee of Lineberger Comprehensive Cancer Center and the Institutional Review Board of the University of North Carolina.

Study Design

This was a phase I single-center trial, and the primary objective was to determine the DLT and the MTD of nab-paclitaxel in combination with gemcitabine. The secondary objectives were to evaluate the efficacy and toxicity of the combination of nab-paclitaxel and gemcitabine. The trial used a standard 3-patient cohort dose escalation design. Three patients were treated at the initial dose level, and if no first cycle DLTs were observed, three additional patients were treated at the next dose level. If one of the three initial patients experienced a DLT at any given dose level, three additional patients were treated at the same dose level. If a DLT occurred in at least two patients at any dose level, dose escalation was halted, and the next three patients were enrolled at the next lower dose level. The MTD and the recommended treatment dose for phase II trials was defined as the highest dose levels that fewer than two of six patients experienced DLT in cycle one. The cohort at the MTD and recommended dose for phase II trials could be expanded to obtain additional efficacy and toxicity information about this dose level. The toxicities observed in the patients on the expanded cohort were not included in the determination of the DLT or MTD.

Study Treatment

Patients received gemcitabine 1000 mg/m² on days 1, 8 and nab-paclitaxel on day 1 every 21 days, and the dose of nab-paclitaxel depended on the patient's cohort. Patients received gemcitabine infused over 30 minutes, followed by a 30-minute infusion of nab-paclitaxel on day 1, and gemcit-

TABLE 1. Inclusion and Exclusion Criteria and Dose-Limiting Toxicities

Inclusion criteria

1. Histologically or cytologically documented solid tumors
2. Measurable disease by RECIST
3. Patients must have progressed on standard therapy, not be a candidate for standard therapy, or have a disease or disease status for which there is no defined standard therapy
4. Age >18 yr
5. Eastern Cooperative Oncology Group (ECOG) functional status of 0–2
6. Adequate organ function defined as:
Renal: serum creatinine $\leq 1.5 \times \text{ULN}$ or Cockcroft calculated creatinine clearance of ≥ 60 ml/min
Hepatic: transaminases $\leq 2.5 \times \text{ULN}$ and total bilirubin in normal range
Bone marrow: ANC $\geq 1.5 \times 10^6/\text{l}$, platelet count $\geq 100,000 \times 10^6/\text{l}$
7. Life expectancy of at least 8 wk

Exclusion criteria

1. Previous anaphylactic reaction or severe allergic reaction to paclitaxel and/or docetaxel
2. Previous anaphylactic reaction or severe allergic reaction to gemcitabine
3. Symptomatic brain metastases
4. Inability to sign informed consent
5. Pregnant or lactating women
6. Active infectious process that will require treatment with antibiotics for greater than 4 wk
7. Uncontrolled congestive heart failure
8. Symptomatic coronary artery disease or heart block
9. Myocardial infarction within the last 3 months
10. Chemotherapy, radiation therapy or any other treatment for malignancy within the last 3 wk
11. Grade ≥ 2 peripheral neuropathy at baseline assessment from any cause
12. Irradiation of >25% of bone marrow
13. Prior exposure to nitrosureas
14. Prior exposure to >6 cycles of alkylating agents
15. Prior exposure to >2 cycles of mitomycin
16. Treatment with >3 previous lines of cytotoxic therapy for metastatic disease

Dose limiting toxicities based on first cycle toxicities*

1. Grade ≥ 3 nonhematological toxicity
2. Grade 4 thrombocytopenia or anemia
3. Grade 4 neutropenia lasting ≥ 7 days
4. Dose delay of initiating the second cycle of >2 wk
5. Day 8 gemcitabine being held related to ANC $< 500 \times 10^6/\text{l}$ or platelet count $< 50,000 \times 10^6/\text{l}$

ULN, upper limit of normal; ANC, absolute neutrophil count; RECIST, Response Evaluation Criteria in Solid Tumors.

*Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0.

abine was infused over 30 minutes on day 8. Dose adjustments for the day 8 gemcitabine were as follows: 100% of the dose if absolute neutrophil count (ANC) was $\geq 1000 \times 10^6/\text{l}$ and platelet count $\geq 100,000 \times 10^6/\text{l}$, and 75% of the dose if the ANC 500–999 $\times 10^6/\text{l}$ or platelet count 50,000 to 99,000 $\times 10^6/\text{l}$. The day 8 dose of gemcitabine was not

administered if the ANC was $<500 \times 10^6/l$ or the platelet count $<50,000 \times 10^6/l$. The doses of nab-paclitaxel and gemcitabine were calculated using the patient's body surface area, with doses capped at a maximum body surface area of 2.0. Patients were treated until disease progression, unacceptable toxicity, two cycles after maximal response or a maximum of six cycles at the discretion of the treating physician.

Patients received antiemetic therapy with dexamethasone before each treatment with nab-paclitaxel and gemcitabine on day 1 and dexamethasone alone before treatment with single agent gemcitabine on day 8. No additional premedications for hypersensitivity reactions were given. Nab-paclitaxel (Abraxane) and gemcitabine (Gemzar) were supplied by the manufacturers. The use of growth colony stimulating factors was prohibited during the first cycle, and could be used after the first cycle if indicated following the American Society of Clinical Oncology guidelines.¹² The use of erythropoietin stimulating agents was permitted and based on the American Society of Clinical Oncology guidelines available at the time trial was performed.¹³

RESULTS

Eighteen patients were consented for this trial, and 15 patients are considered evaluable. Three patients are noneva-

TABLE 2. Patient Characteristics at Baseline

Characteristic	No.
Sample size	15
Median age (range) in years	62 (35–75)
ECOG performance status	
0	6
1	8
2	1
Gender	
Male	8
Female	7
Race	
White	14
Black	1
Median number of previous cytotoxic therapies	3
Malignancy	
Non-small cell lung cancer	8
Small cell lung cancer	6
Esophageal cancer	1

ECOG, Eastern Cooperative Oncology Group.

uable for the following reasons: progressive disease prior to initiating protocol therapy ($n = 1$), withdrawal of consent after cycle 1 day 1 therapy ($n = 1$), and inability to meet screening laboratory eligibility criteria ($n = 1$). The demographics of the evaluable 15 patients are presented in Table 2. The majority of the patients were: white ($n = 14$), male ($n = 8$) and had non-small cell or small cell lung cancer ($n = 14$). The median number of prior therapies was 3.

Determination of the Maximum Tolerated Dose

No DLT were observed in the first cohort (nab-paclitaxel 260 mg/m² every 21 days). At the second-dose level (nab-paclitaxel 300 mg/m² every 21 days), one of the 6 patients experienced DLT (omission of day 8 gemcitabine due to ANC $<500 \times 10^6/l$). In the third dose cohort (340 mg/m² every 21 days), 2 of the first 3 patients experienced a DLT (grade 3 fatigue/asthenia and grade 3 anorexia in one patient, grade 3 rash and grade 3 pruritis in one patient). The MTD and recommended dose for phase II trials is nab-paclitaxel is 300 mg/m² on day 1 in combination with gemcitabine 1000 mg/m² on days 1, 8, every 21 days.

Toxicities

The hematological toxicities for all the cycles are summarized in Table 3. The rate of severe hematological toxicity was low with grade 4 neutropenia observed in one cycle, and one episode of febrile neutropenia. Growth colony stimulating factors supportive therapy was not used during any of the cycles. Grade 3 anemia and grade 3 thrombocytopenia were each observed in one cycle. Two patients were treated with erythropoietin stimulating agents for a total of 4 cycles, and one patient had transfusion of 2 units packed red blood cells. The main nonhematological toxicities consisted of sensory neuropathy, nausea, vomiting, fatigue, and alopecia. The nonhematological toxicities for all patients are summarized in Table 4. One patient in the expanded cohort developed grade 3 pneumonitis, which was attributed to the gemcitabine. The patient was treated with supplemental oxygen and corticosteroids with improvement of his dyspnea and oxygenation, and did not continue treatment due to evidence of disease progression and toxicity. Two patients discontinued therapy due to treatment related toxicity: one patient experienced grade 3 fatigue/asthenia and grade 3 anorexia after cycle 1 of nab-paclitaxel at a dose of 340 mg/m² and while eligible for further therapy after a dose reduction, elected not to continue and one patient experienced grade 3 sensory neuropathy which did not resolve after a 2 week treatment delay. This patient had underlying diabetes and had previously received

TABLE 3. Treatment-Related Hematological Toxicity^a

Nab-Paclitaxel (mg/m ²)	No. Patients	No. Cycles	Neutropenia Grade				Anemia Grade				Thrombocytopenia Grade				Febrile Neutropenia Grade			
			1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4
260	3	17	7	1	2	0	5	1	0	0	3	0	0	0	0	0	1	0
300	9	39	11	7	9	1	15	3	1	0	9	0	1	0	0	0	0	0
340	3	3	0	2	3	0	2	1	0	0	1	0	0	0	0	0	0	0

^a Worst grade of individual toxicity per cycle reported.

TABLE 4. Treatment Related Nonhematological Toxicities^a

Nab-paclitaxel	260 mg/m ²				300 mg/m ²				340 mg/m ²			
	No. patients				No. cycles				Grade			
	1	2	3	4	1	2	3	4	1	2	3	4
No. patients	3				9				3			
No. cycles	17				39				3			
Sensory neuropathy	5	1	1	0	10	3	1	0	1	1	0	0
Nausea	0	1	0	0	11	4	0	0	2	1	0	0
Vomiting	0	0	0	0	5	2	0	0	0	0	0	0
Diarrhea	1	0	0	0	2	1	0	0	0	0	0	0
Myalgia	0	0	0	0	4	2	0	0	2	0	0	0
Arthralgias	0	0	0	0	2	1	0	0	1	1	0	0
Fatigue/asthenia	2	0	0	0	13	4	0	0	1	0	1	0
Fever ^b	0	0	0	0	4	0	0	0	2	0	0	0
Rash ^c	1	0	0	0	2	0	0	0	1	0	1	0
Pruritis	0	0	0	0	2	1	0	0	0	0	1	0
Peumonitis	0	0	0	0	0	0	1	0	0	0	0	0
Transaminitis	0	0	0	0	3	2	0	0	0	0	0	0
Electrolyte ^d	0	0	0	0	1	0	0	0	0	0	1	0
Dehydration	0	0	0	0	2	1	0	0	0	1	0	0
Alopecia ^e												

^a Worst grade of individual toxicity per cycle reported.

^b Fever in absence of neutropenia or identifiable infection.

^c At nab-paclitaxel dose of 340 mg/m² grade 3 rash consisted of diffuse erythema over >50% of the body associated with grade 3 pruritis.

^d At nab-paclitaxel dose of 300 mg/m² grade 1 hyponatremia; at nab-paclitaxel dose of 340 mg/m² grade 3 hyponatremia.

^e All patients experienced grade 2 alopecia.

paclitaxel: she received nab-paclitaxel 300 mg/m² on cycle 1 and 260 mg/m² on cycle 2. A second patient developed grade 3 sensory neuropathy after the second cycle, but did not have a history of diabetes or previous paclitaxel therapy, and discontinued therapy because of progressive disease.

Treatment Administration

A total of 59 cycles were administered and no patients experienced any treatment delays related to myelosuppression. Patients received treatment with nab-paclitaxel at 3 different doses of nab-paclitaxel: 260 mg/m² (17 cycles), 300 mg/m² (39 cycles), and 340 mg/m² (3 cycles). Four patients underwent dose reduction of the nab-paclitaxel; the 3 patients who experienced a DLT, and one patient who initiated therapy at 340 mg/m² had the nab-paclitaxel dose reduced when it was determined that the dose level has an unacceptable rate of toxicity. The day 8 gemcitabine was successfully administered on 58 of the 59 cycles. One patient had cycle 1 day 8 gemcitabine withheld due to neutropenia (and was considered a DLT), and after dose adjustment of the nab-paclitaxel received the day 8 gemcitabine on the second-cycle. On 7 cycles, the dose of the day 8 gemcitabine was adjusted from 1000 to 750 mg/m². The dose intensity of the gemcitabine, defined as the dose patients received divided by full dose prescribed per protocol, was 98%, and for the day 8 gemcitabine was 95%.

Response

Thirteen of the 15 patients are evaluable for response; 2 patients discontinued therapy and are nonevaluable since response was either not assessed or confirmed. The best

TABLE 5. Best Response as Assessed by RECIST¹¹

Malignancy	PR	SD	PD	NE ^a
NSCLC	3	3	1	1
SCLC	3	0	2	1
Esophageal	0	1	0	0

RECIST, Response Evaluation Criteria in Solid Tumors; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; PR, partial response; SD, stable disease; PD, progressive disease; NE, nonevaluable.

^a Two patients were nonevaluable due to toxicity; one patient had grade 3 asthenia and anorexia after the first cycle, one patient had grade 3 sensory neuropathy after the second cycle and response was not confirmed.

response per patient recorded from the start of treatment until completion of protocol therapy that was confirmed on repeating imaging ≥ 4 weeks is reported on Table 5. Partial responses were seen among patients with small cell lung cancer (SCLC) ($n = 3$), and NSCLC ($n = 3$); 4 patients experienced stable disease [NSCLC ($n = 3$) and esophageal cancer ($n = 1$)].

DISCUSSION

This phase I trial demonstrates that the MTD of nab-paclitaxel was 300 mg/m² on day 1 in combination with gemcitabine 1000 mg/m² on days 1, 8 on an every 21-day schedule. This result is concordant with the findings from other early phase trials of this agent alone or in combination.^{14–16} This dose of nab-paclitaxel did not seem to significantly compromise the treatment administration of the day 8 gemcitabine.

Two patients did develop grade 3 sensory neuropathy on this trial; both after two cycles of treatment. The incidence of grade 3 sensory neuropathy was higher with nab-paclitaxel than paclitaxel in the phase III trial (10% versus 2%, respectively; $p < 0.001$).¹⁷ The incidence of sensory neuropathy is known to increase significantly after four cycles of carboplatin and paclitaxel,¹⁸ and the incidence of sensory neuropathy related to nab-paclitaxel may be cumulative or dose dependent. Given the variability in dose and number of cycles of nab-paclitaxel received in previous trials, it is difficult to make a definitive conclusion about the relationship between these factors and the rate of grade 3 sensory neuropathy. In a recent phase II dose escalation trial of carboplatin and nab-paclitaxel, the incidence of sensory neuropathy appeared to increase with increasing dose of nab-paclitaxel.⁵ In this trial, all patients received carboplatin (area under the curve = 6), and patients received nab-paclitaxel 225, 260, 300, or 340 mg/m² every 21 days depending on the cohort. The incidence of grade 3 sensory neuropathy was 8%, 8%, 12%, and 24%, respectively. Future clinical trials that investigate the dose and schedule of nab-paclitaxel should include close monitoring for this toxicity. Preliminary evidence indicates that prolonging the infusion time of nab-paclitaxel from the standard 30 minutes to 2 hours may decrease the incidence of grade 2 and 3 sensory neuropathy, presumably by decreasing the peak plasma levels of nab-paclitaxel.¹⁹

This combination demonstrated significant activity: 6 patients experienced a partial response and 4 patients experienced stable disease in this previously treated population (median number of previous cytotoxic therapies = 3). However, these results should be interpreted with caution given the small sample size and the fact that gemcitabine and paclitaxel as single agents or in combination have demonstrated significant activity in second-line therapy for NSCLC and SCLC.^{20–23} Phase II trials in specific patient populations will be required to assess the activity of this combination. This combination may prove to be a nonplatinum alternative regimen for patients with advanced NSCLC if phase II studies confirm the preliminary indications of activity observed in the previously treated patients enrolled in our trial.

The combination of gemcitabine and paclitaxel has demonstrated similar efficacy and toxicity in comparison to platinum-based doublet chemotherapy in advanced NSCLC in two large phase III trials.^{8,9} The rate of neutropenia observed with gemcitabine and paclitaxel in these trials has been within acceptable limits. In the phase III trial by Kosmidis et al., the percentage of patients experiencing grade 3 and 4 neutropenia on gemcitabine and paclitaxel treatment arm ($n = 239$) was 10% and 5%, respectively.⁹ In the phase III trial by Treat et al., the percentage of patients on the gemcitabine and paclitaxel treatment arm ($n = 328$) experiencing grade 3 and 4 neutropenia and febrile neutropenia was 12% and 9%, respectively, and 3% and 1%, respectively. A low incidence of grade 4 neutropenia (1 of 59 cycles) was observed in this trial. However, the clinical benefit of the substitution of nab-paclitaxel for paclitaxel in this combination to reduce the incidence of neutropenia, without a reduction of other toxicities or an improvement in efficacy, is

debatable. The low incidence on neutropenia may make the combination of gemcitabine and nab-paclitaxel an attractive chemotherapy combination to investigate with novel targeted agents that may be associated with severe neutropenia. For instance, the addition of bevacizumab to carboplatin and paclitaxel in advanced NSCLC resulted in a statistically significant increase in the rate of grade 4 neutropenia and febrile neutropenia in comparison to standard carboplatin and paclitaxel.²⁴ Multitargeted tyrosine kinase inhibitors, such as sunitinib or sorafenib, have demonstrated activity in NSCLC, but may cause myelosuppression as well.^{25,26}

One deficiency in this trial was that a pharmacokinetic analysis was not performed. A phase I trial by Kroep et al. investigated the schedule of gemcitabine 1000 mg/m² on days 1, and 8 and escalating doses of paclitaxel (150 and 200 mg/m²) on day 1 every 21 days in 18 patients with advanced NSCLC.²⁷ Paclitaxel did not affect the pharmacokinetics of gemcitabine, and nor did gemcitabine affect the pharmacokinetics of paclitaxel, and the conclusion of the trial was that no drug-drug interactions were seen with this combination. A phase I trial by Folgi et al. investigated for a potential pharmacokinetic interaction between the two drugs with a treatment schedule of paclitaxel 100 mg/m² and escalating doses of gemcitabine (1500, 1750, and 2000 mg/m²) on days 1, 8, and 15 every 28 days in 15 patients with advanced NSCLC.²⁸ This trial demonstrated no interaction between the two drugs. A phase I trial by De Pas et al. investigated escalating doses of gemcitabine (800–2000 mg/m²) and paclitaxel (60–100 mg/m²) on days 1, 8, and 15 every 28 days in 35 patients with advanced NSCLC.²⁹ No pharmacokinetic interactions were observed. All three of these phase I trials used the same gemcitabine infusion time (30 minutes) as our trial. On the basis of the data from these previous trials that had investigated the pharmacokinetics of gemcitabine and paclitaxel on several different schedules in a similar patient population, we determined that the probability of a drug-drug interaction between nab-paclitaxel and gemcitabine was low, and elected not to pursue a pharmacokinetic analysis of the two drugs.

In conclusion, the maximum tolerated dose and the dose recommended dose for phase II trials of nab-paclitaxel is 300 mg/m² on day 1 in combination with gemcitabine 1000 mg/m² on days 1, 8 every 21 days. In this previously treated patient population with NSCLC, SCLC, and esophageal cancer, the combination of gemcitabine and nab-paclitaxel revealed acceptable toxicity and encouraging preliminary evidence of activity.

ACKNOWLEDGMENTS

Supported by grant for General Clinical Research Center (Grant # RR00046), Abraxis Bioscience, and Lilly Oncology.

REFERENCES

1. Crown J, O'Leary M. The taxanes: an update. *Lancet* 2000;355:1176–1178.
2. Gradishar WJ, Tjulandin S, Davidson N, et al. Superior efficacy of albumin-bound paclitaxel, ABI-007, compared with polyethylated castor oil-based paclitaxel in women with metastatic breast cancer: results of a phase III Trial. *J Clin Oncol* 2005;23:1–10.

3. Rizvi NA, Riely GJ, Azzoli CG, et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. *J Clin Oncol* 2008; 26:639–643.
4. Allerton JP, Hagenstad CT, Webb RT, et al. A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first line treatment of advanced non-small cell lung cancer (NSCLC). *J Clin Oncol* 2006;24(18S):abstract 7127. 2006 ASCO Annual Meetings Proceedings.
5. Hawkins MJ, Georgy M, Makhson A, et al. Dose escalation study of nab-paclitaxel followed by carboplatin a first line therapy in advanced non-small cell lung cancer (NSCLC). *J Clin Oncol* 2006;24(18S): abstract 7132. 2006 ASCO Annual Meetings Proceedings.
6. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. *Ann Oncol* 2006;17:1263–1268.
7. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology Treatment of Unresectable Non-Small Cell Lung Cancer Guideline: Update 2003. *J Clin Oncol* 2004;22:330–353.
8. Treat J, Belani CP, Edelman MJ, et al. A randomized phase III trial of gemcitabine in combination with carboplatin or paclitaxel versus paclitaxel plus carboplatin in advanced (Stage IIIB, IV) non-small cell lung cancer (NSCLC): Update of the Alpha Oncology trial (A1-99002L). *J Clin Oncol* 2005;23(16S):abstract 7025; page 627s.
9. Kosmidis P, Mylonakis N, Nicolaides C, et al. Paclitaxel plus carboplatin versus gemcitabine plus paclitaxel in advanced non-small cell lung cancer: a phase III randomized trial. *J Clinical Oncol* 2002;20:3578–3585.
10. Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): first report of overall survival. *J Clin Oncol* 2004;22(14S):abstract 510.
11. Therasse P, Arbuuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 2000;92:205–216.
12. Ozer H, Armitage JO, Bennett CL, et al. 2000 update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. American Society of Clinical Oncology Growth Factors Expert Panel. *J Clin Oncol* 2000;18:3558–3585.
13. Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. *J Clin Oncol* 2002;20:4083–4107.
14. Ibrahim NK, Desai N, Legha S, et al. Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. *Clin Cancer Res* 2002;8:1038–1044.
15. Ibrahim NK, Samuels B, Page R, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. *J Clin Oncol* 2005;23:6019–6026.
16. Stinchcombe TE, Socinski MA, Walko CM, et al. Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors. *Cancer Chemother Pharmacol* 2007;60:759–766.
17. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. *J Clin Oncol* 2005;23:7794–7803.
18. Socinski MA, Schell MJ, Peterman A, et al. Phase III trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage IIIB/IV non-small-cell lung cancer. *J Clin Oncol* 2002;20:1335–1343.
19. James LP, Kris MG, Heelan RT, et al. A phase II study to determine if sensory neuropathy of nab-paclitaxel can be reduced by prolonging infusion in patients with non-small cell lung cancer (NSCLC). *J Clin Oncol* 2007;25(18S):abstract 18087. 2007 ASCO Annual Meeting Proceedings Part I.
20. Crino L, Mosconi A, Scagliotti G, Selvaggi G, Novello S, Rinaldi M. Gemcitabine as second-line treatment for advanced non-small cell lung cancer: A phase II trial. *J Clin Oncol* 1999;17:2081–2085.
21. Masters GA, Declerck L, Blanke C, et al. Phase II trial of gemcitabine in refractory or relapsed small-cell lung cancer: Eastern Cooperative Oncology Group Trial 1597. *J Clin Oncol* 2003;21:1550–1555.
22. Wozniak AJ, Belzer K, Heilbrun LK, et al. Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer. *Clin Lung Cancer* 2007;8:313–318.
23. Gillenwater H, Tynan M, Natoli S, Schell M, Socinski M. Second-line gemcitabine in refractory stage IV non-small cell lung cancer: a phase II trial. *Clin Lung Cancer* 2000;2:133–138.
24. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. *N Engl J Med* 2006;355: 2542–2550.
25. Socinski M, Novello S, Sanchez JM, et al. Efficacy and safety of sunitinib in previously treated, advanced non-small cell lung cancer: Preliminary Results of a multicenter phase II trial. *J Clin Oncol (Ann Meeting Proc)* 2006;24(18S):7001.
26. Gatzemeier U, Blumenschein G, Fosella F, et al. Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma. *J Clin Oncol (Annual Meeting Proc)* 2006;24(18S):7002.
27. Kroep JR, Giaccone G, Voorn DA, et al. Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. *J Clin Oncol* 1999;17:2190–2197.
28. Fogli S, Danesi R, De Braud F, et al. Drug distribution and pharmacokinetic/pharmacodynamic relationship of paclitaxel and gemcitabine in patients with non-small-cell lung cancer. *Ann Oncol* 2001;12(11):1553–9.
29. De Pas T, de Braud F, Danesi R, et al. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer. *Ann Oncol* 2000;11(7):821–7.